Cancer Aware · Patient & Family Guide

Understanding the Pathology Report

Your pathology report brings together the tissue findings that guide staging and postoperative treatment. It is normal to need a clinician to translate the terminology.

Educational information for patients and families. This guide supports, but does not replace, individualized medical advice. It cannot diagnose, stage cancer or prescribe treatment.

All 25 chapters

Chapter 8 of 25

Four molecular groups — read alongside stage and histology
  1. POLEmut: qualifying pathogenic proofreading mutation
  2. MMRd: defective DNA mismatch repair
  3. p53abn: abnormal p53 biology after classifier integration
  4. NSMP: none of the other groups; grade and ER refine risk

What you will learn

  • Identify the findings that most often change treatment.
  • Distinguish muscle invasion, vessel invasion and nodal spread.
  • Understand why an integrated final report may take time.

The core diagnosis

The report names the histological subtype and grade where applicable. Endometrioid carcinoma is graded differently from histologies that are considered high grade by definition. A report from a biopsy may be provisional; the hysterectomy specimen can reveal a different component or provide a more reliable assessment of grade.

Myometrial invasion describes how far cancer extends into the uterine muscle. The report may give millimetres and the percentage of total muscle thickness involved. Less than half and half or more are important boundaries in several staging and risk categories. Tumour size is also recorded, but size alone does not replace invasion, histology or molecular information.

Local spread and lymphovascular invasion

Cervical stromal invasion means cancer has entered the supporting tissue of the cervix. Involvement of cervical glands alone is different. The serosa is the outer uterine surface; involvement there or in ovaries, tubes, vagina or parametrial tissues may alter stage. The exact finding matters more than the general phrase “extension.”

Lymphovascular space invasion, or LVSI, means tumour cells are seen within small blood or lymphatic channels. It is not the same as a positive lymph node. Pathologists distinguish absent, focal and substantial LVSI. FIGO 2023 uses substantial LVSI as a staging feature in nonaggressive histology; its assessment needs expertise and should not be inferred from a single word in an incomplete report.

Lymph nodes and margins

FindingMeaning
Negative nodeNo tumour identified using the assessment performed
Isolated tumour cellsVery small deposits, recorded separately; do not alone upstage disease
MicrometastasisA small metastatic deposit, with staging implications
MacrometastasisA larger metastatic deposit
Positive marginCancer reaches an examined surgical cut edge

Sentinel nodes may undergo ultrastaging, which uses additional sections and sometimes stains to detect small deposits. The number of nodes removed is not by itself a measure of surgical quality: a correctly performed sentinel-node algorithm differs from systematic lymphadenectomy. Ask whether mapping was successful and how any unmapped side was managed.

Molecular information

The integrated report may include MMR protein staining, p53 staining, a pathogenic POLE result and ER expression. Some tests return separately. MMR deficiency may lead to MLH1 methylation testing or genetic counselling; it does not automatically establish an inherited condition. HER2 is selectively useful, particularly in some advanced or recurrent aggressive cancers.

A “variant of uncertain significance” is not a proven actionable mutation. Equivocal staining or unexpected combinations may need expert review or further tests. The four-group classification should be assigned using a validated workflow, rather than selecting whichever individual result sounds most reassuring.

Turning a report into a care plan

Ask the team to summarize the final FIGO stage, molecular group and recurrence-risk category separately. Stage describes a structured combination of extent and, in FIGO 2023, certain biological findings. Risk grouping helps choose additional treatment. These are related but not interchangeable labels.

Questions and take-home messages

Useful questions include: Is this the final report? Which findings make additional treatment useful? Are any molecular tests pending? Would specialist pathology review change the plan? Keep the full report, including addenda, because a one-line discharge summary may omit information relevant to future recurrence treatment or family counselling.

Related chapters

References and review status

Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.

Evidence scope and update policy